Director/PDMR Shareholding

Summary by AI BETAClose X

Hikma Pharmaceuticals PLC announced that several Persons Discharging Managerial Responsibility (PDMRs) received ordinary shares on June 1, 2026, due to the vesting of conditional awards under the 2023 Long-Term Incentive Plan (LTIP) and the 2014 Executive Incentive Plan (EIP) Element C. Specifically, Said Darwazah received 91,812 LTIP shares and 19,761 EIP shares, Mazen Darwazah received 72,763 LTIP shares and 20,650 EIP shares, Khalid Nabilsi received 51,650 LTIP shares and 22,209 EIP shares, Bassam Kanaan received 52,640 LTIP shares and 20,982 EIP shares, and Hussein Arkhagha received 28,631 LTIP shares and 12,406 EIP shares. All these individuals retained their shares. In contrast, Susan Ringdal sold 38,222 shares, comprising 26,558 LTIP and 11,664 EIP shares, at a price of £14.49 per share, totaling £553,748.83.

Disclaimer*

Hikma Pharmaceuticals Plc
02 June 2026
 

 

Hikma Pharmaceuticals PLC - LTIP and EIP Vesting

 

LONDON, 2 June 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (Nasdaq Dubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMRs") have received shares as a result of the vesting of their conditional share awards which were granted on 30 May 2023 under the 2023 Long-Term Incentive Plan ("LTIP") and 2014 Executive Incentive Plan ("EIP") Element C.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 91,812

Nil

EIP Award, Element C: 19,761

d)

Aggregated information

Price(s): nil

Volume(s): 111,573

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman and Deputy CEO, MENA

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 72,763

Nil

EIP Award, Element C: 20,650

d)

Aggregated information

Price(s): nil

Volume(s): 93,413

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

Deputy CEO, North America and Europe

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 51,650

Nil

EIP Award, Element C: 22,209

d)

Aggregated information

Price(s): nil

Volume(s): 73,859

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 52,640

Nil

EIP Award, Element C: 20,982

d)

Aggregated information

Price(s): nil

Volume(s): 73,622

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

Hussein Arkhagha

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hussein Arkhagha

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 28,631

Nil

EIP Award, Element C: 12,406

d)

Aggregated information

Price(s): nil

Volume(s): 41,037

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 26,558

Nil

EIP Award, Element C: 11,664

d)

Aggregated information

Price(s): nil

Volume(s): 38,222

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each ("Shares")

ID Code: GB00B0LCW083

b)

Nature of the transaction

All shares sold following the vesting of conditional awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.49

LTIP Award: 26,558

£14.49

EIP Award, Element C: 11,664

d)

Aggregated information

Price(s): £14.49

Volume(s): 38,222

Total(s): £553,748.83

e)

Date of the transaction

1 June 2026

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Helen Middlemist
Group Company Secretary

+44 (0)20 7399 2760

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings